Tildrakizumab
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Tildrakizumab is a monoclonal antibody that targets IL-23. IL-23 is part of the IL-12 cytokine family,
the master regulator of the TH1 pathway which drives major chronic inflammatory diseases, including
Crohn’s disease, psoriasis, rheumatoid arthritis, and multiple sclerosis.
Analyst Outlook
While tildrakizumab (Merck & Co/Sun Pharma) has demonstrated promising efficacy to date,
Datamonitor Healthcare believes its uptake in psoriasis will be restricted by its lack of differentiation
from the first-to-market interleukin (IL)-12/23 inhibitor Stelara (ustekinumab; Johnson & Johnson), as
well as the marketed IL-17A inhibitors Cosentyx (secukinumab; Novartis) and Taltz (ixekizumab; Eli
Lilly). Dermatologists also note that tildrakizumab’s efficacy is considered comparable to that of the
other late-phase IL-23 inhibitors, namely guselkumab (Johnson & Johnson/MorphoSys) and ABBV-066
(risankizumab; AbbVie/Boehringer Ingelheim), which negatively impacts its commercial attractiveness
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 tildrakizumab : Psoriasis
LIST OF FIGURES
10 Figure 1: Phase II trial design for tildrakizumab
11 Figure 2: Tildrakizumab for psoriasis – SWOT analysis
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of tildrakizumab in psoriasis
13 Figure 4: Datamonitor Healthcare’s drug assessment summary of tildrakizumab in psoriasis
LIST OF TABLES
4 Table 1: Tildrakizumab drug profile
7 Table 2: Tildrakizumab pivotal late-phase trials in psoriasis
10 Table 3: Week 16 results for Phase II trial of tildrakizumab in psoriasis
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Acute Myelogenous Leukemia (AML) KOL Interview 
Sign up to the